| Drug Name | ***0157 |
| Description |
Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting enzyme that catalyzes the conversion of tryptophan into kynurenine. The depletion of tryptophan and the increase in kynurenine have important immunosuppressive functions in cancers. A novel small molecule inhibitor of IDO1 is in preclinical development and may be a therapeutic opportunity in cancer immunotherapy beyond checkpoint blockade. |
| Target | IDO1 |
| Drug Modality | Small Molecule |
| Indication | Cancer |
| Product Category | Cancer Immunotherapy |
| Mechanism of Action | Inhibiting IDO1 and decreasing kynurenine levels to reverse immunosuppression |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |